India Pharma - Cherry Picking Is Key To Better Returns: Dolat Capital

Dolat Capital Report

Pharma sector has underperformed Nifty index in last 12 months (Nifty Pharma -3.1% versus Nifty up 0.3%).

The companies faced multiple headwinds, and hence stock performance has mirrored that with time and correction. While we do believe that the pharmaceutical sector has underperformed broader index over the last year, valuations which were on higher side have also settled to reasonable levels, however we still hold the view that pharmaceutical sector is still very much bottoms up and is definitely not a one size fit all story at this juncture.

The year FY23 has hitherto been challenging for the pharma sector, however, strong India business, and gradual abatement in pricing scenario in the U.S., we see signs of earnings recovery in FY24E which will be a function of beneficial base effect.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.